Non small cell lung cancer is a type of cancer that commonly affects the lungs and spreads more slowly than its counterpart, small cell lung cancer. This particular form accounts for about 85% of all lung cancers, making it the most prevalent subtype. Non small cell lung cancer can be further categorized into three main types: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma often starts in cells that produce mucus and is typically found on the outer parts of the lungs. Squamous cell carcinoma usually arises in the lining of bronchial tubes and tends to cause symptoms like coughing or shortness of breath earlier on. Large cell carcinoma refers to tumors that are difficult to classify as either adenocarcinoma or squamous cell carcinoma due to their unique characteristics. Although non small cell lung cancer progresses at a slower pace, proper diagnosis at an early stage remains vital for effective treatment options such as surgery, radiation therapy, chemotherapy, targeted therapies or immunotherapy tailored according to individual cases and preferences.
1.
enhancing survivors of brain tumors' quality of life.
2.
Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.
3.
A protein with new anticancer activity has been identified
4.
Studies point to redlining as a 'perfect storm' for breast cancer
5.
Enzalutamide vs Abiraterone: Which is Better for mCSPC?
1.
From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma
2.
Future of Chemotherapy: New Advances, Treatments & Survival Rates Transforming Cancer Care
3.
What is Hemorrhagic Cystitis and How to Manage its Symptoms
4.
Fc Receptor Mediated Pharmacology of Therapeutic Antibodies
5.
Progressive Strategies in Oncology and Patient Outcomes
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
4.
Managing Common Side Effects During Cancer Treatment
5.
Clinical Insights in Oncology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation